Table 2.
Details on therapeutic lines and information on refractoriness in MMR patients.
| Diagnosis | Previous Treatments | Therapeutic lines received (n.) | Refractoriness | |||
|---|---|---|---|---|---|---|
| Thal/IMiDs (Y/N) | PIs (Y/N) | ASCT (Y/N) | PIs (Y/N) | IMiDs (Y/N) | ||
| MMR1 | Y | Y | N | 2 | N | Y |
| MMR2 | – | – | – | 1 | NV | NV |
| MMR3 | Y | Y | N | 2 | N | Y |
| MMR4 | N | Y | N | 1 | Y | |
| MMR5 | Y | Y | Y | 1 | N | N |
| MMR6 | Y | Y | N | >3 | N | N |
| MMR7 | Y | N | N | 2 | Y | |
| MMR8 | N | Y | N | 1 | Y | |
| MMR9 | N | Y | N | 1 | Y | |
| MMR10 | N | Y | N | 1 | N | |
| MMR11 | N | Y | N | 1 | Y | |
| MMR12 | N | Y | N | 1 | Y | |
| MMR13 | N | Y | N | 1 | N | |
| MMR14 | Y | Y | Y | 1 | N | N |
| MMR15 | Y | Y | Y | >3 | Y | Y |
| MMR16 | N | Y | N | 1 | N | |
| MMR17 | N | Y | N | 1 | N | |
| MMR18 | Y | N | N | 1 | Y | |
| MMR19 | Y | Y | N | 2 | N | N |
| MMR20 | Y | Y | N | 3 | N | N |
| MMR21 | N | Y | N | 1 | Y | |
| MMR22 | Y | Y | Y | 3 | N | N |
| MMR23 | N | Y | N | 1 | Y | |
| MMR24 | Y | Y | N | 3 | N | Y |
| MMR25 | N | Y | N | 1 | N | |
| MMR26 | Y | N | N | 1 | N | |
| MMR27 | Y | Y | Y | 1 | N | N |
| MMR28 | Y | Y | Y | 1 | N | N |
| MMR29 | N | Y | N | 1 | N | |
| MMR30 | N | Y | N | 1 | N | |
| MMR31 | Y | Y | Y | >3 | Y | Y |
| MMR32 | Y | Y | Y | 1 | N | N |
| MMR33 | Y | Y | Y | >3 | Y | Y |
| MMR34 | Y | N | N | 2 | Y | |
| MMR35 | Y | Y | N | 3 | Y | Y |
| MMR36 | Y | Y | N | >3 | Y | Y |
MMR, relapsed/refractory multiple myeloma; Thal, Thalidomide; IMiDs, immunomodulatory drugs; PIs, proteasome inhibitors; ASCT, autologous stem cell transplantation; Y, Yes; N, Not; NV, not evaluable (patient enrolled in a blind study, not yet concluded); n., number.